Sanuwave Health will present its Q2 2026 financial results via conference call on August 7, 2026.
Quiver AI Summary
Sanuwave Health, Inc. will host a live conference call on August 7, 2026, at 8:30 AM (ET) to discuss its Q2 2026 financial results. Participants can join the call via telephone or through a live webcast link provided on the company's website. A replay of the call will be available until August 21, 2026. Sanuwave specializes in FDA-approved wound care products and focuses on developing non-invasive medical systems for tissue repair and regeneration. The press release includes forward-looking statements regarding the company's future performance and emphasizes the associated risks and uncertainties. Investors are encouraged to review these risks in the company's SEC filings.
Potential Positives
- Sanuwave Health is hosting a live conference call to present its Q2 2026 financial results, indicating transparency and engagement with investors.
- The company has a focus on next-generation FDA-approved wound care products, which enhances its credibility and market potential in a growing industry.
- Sanuwave's patented technologies for regenerative medicine highlight innovative advancements in medical treatment, positioning the company as a leader in its field.
- The replay of the conference call and access to materials demonstrates Sanuwave's commitment to investor relations and information dissemination.
Potential Negatives
- The press release contains a warning about forward-looking statements, indicating that future performance is uncertain and may not meet expectations, which could undermine investor confidence.
- Investors are cautioned about various risks that may affect operating results and financial condition, suggesting potential instability within the company.
- The mention of competition as a risk factor highlights potential challenges the company may face in maintaining its market position.
FAQ
When will Sanuwave Health present its Q2 2026 financial results?
Sanuwave Health will present its Q2 2026 financial results on August 7, 2026, at 8:30 AM ET.
How can I access the live conference call?
The live conference call can be accessed by dialing 1-800-274-8461 or 1-203-518-9814, or via the webcast link provided.
What is the conference call's replay information?
A replay of the conference call will be available until August 21, 2026, by calling 1-844-512-2921 or 1-412-317-6671.
What kind of products does Sanuwave Health provide?
Sanuwave Health specializes in FDA-approved wound care products aimed at skin, musculoskeletal, and vascular tissue repair.
Where can I find materials for the conference call?
Materials for the conference call will be available on Sanuwave's investor website at www.sanuwave.com/investors.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SNWV Insider Trading Activity
$SNWV insiders have traded $SNWV stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $SNWV stock by insiders over the last 6 months:
- MANAGEMENT INC. OPALEYE has made 0 purchases and 11 sales selling 122,698 shares for an estimated $2,186,192.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$SNWV Revenue
$SNWV had revenues of $9.6M in Q1 2026. This is an increase of 2.97% from the same period in the prior year.
You can track SNWV financials on Quiver Quantitative's SNWV stock page.
You can access data on SNWV stock through the Quiver Quantitative API.
$SNWV Hedge Fund Activity
We have seen 28 institutional investors add shares of $SNWV stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG added 191,642 shares (+1029.2%) to their portfolio in Q1 2026, for an estimated $3,313,490
- PRAETORIAN PR LLC added 85,000 shares (+32.1%) to their portfolio in Q1 2026, for an estimated $1,469,650
- EVERSOURCE WEALTH ADVISORS, LLC removed 43,054 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $430,540
- HUNTLEIGH ADVISORS, INC. removed 33,445 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $578,264
- RICE HALL JAMES & ASSOCIATES, LLC removed 25,156 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $434,947
- MILLENNIUM MANAGEMENT LLC added 24,669 shares (+inf%) to their portfolio in Q1 2026, for an estimated $426,527
- JANE STREET GROUP, LLC removed 19,666 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $340,025
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
EDEN PRAIRIE, Minn., July 30, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, August 7, 2026, at 8:30 AM (ET) to present its Q2 2026 financial results.
Telephone access to the call will be available by dialing the following numbers:
Participant Dial-in Information
Toll Free:
1-800-274-8461
Toll/International:
1-203-518-9814
Conference ID:
SANUWAVE
OR click the link below to access the live webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1771327&tp_key=110b588de5
Materials for the conference call will be included on the Company’s website at
www.sanuwave.com/investors
.
A replay will be made available through Friday, August 21, 2026:
Toll-Free: 1-844-512-2921
Toll/International: 1-412-317-6671
Replay Access ID: 11162356
About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact:
[email protected]
